Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Лечение артериальной гипертензии: есть ли место для b-адреноблокаторов? - Журнал Системные Гипертензии Том 10, №1
Лечение артериальной гипертензии: есть ли место для b-адреноблокаторов?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Статья посвящена возможностям использования в терапии артериальной гипертензии (АГ) b-адреноблокаторов. Более подробно рассмотрены особенности небиволола, высокоселективного b-адреноблокатора III поколения, оказывающего влияние на функцию эндотелия и стимулирующего синтез NO. Описан возможный механизм ангиопротективного действия препарата. Приведены доказательства антигипертензивной эффективности. Рассмотрены вопросы влияния небиволола на состояние органов-мишеней при АГ, метаболические эффекты небиволола, возможности назначения препарата у больных с сопутствующими заболеваниями.
Ключевые слова: артериальная гипертензия, небиволол.
Key words: hypertension, nebivolol.
Ключевые слова: артериальная гипертензия, небиволол.
________________________________________________
Key words: hypertension, nebivolol.
Полный текст
Список литературы
1. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res 2009; 84 (1): 24–32.
2. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using b-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50: 563–72.
3. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25.
4. Magid DJ, Shetterly SM, Margolis KL et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors vs b-blockers as second-line therapy for hypertension circ. Cardiovasc Qual Outcomes 2010; 3: 453–8.
5. Oğuz A, Uzunlulu M, Yorulmaz E et al. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethy larginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg 2007; 7 (4): 383–7.
6. Zepeda RJ, Castillo R, Rodrigo R et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol 2012; 111 (5): 309–16.
7. Feng MG, Prieto MC, Navar LG. Nebivolol-induced vasodilation of renal afferent arterioles involves b3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol 2012; 303 (5): 775–82.
8. Lewin A, Lasseter KC, Dong F, Whalen JC. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. J Am Soc Hypertens 2012; 6 (3): 228–36.
9. Acelajado MC, Pisoni R, Dudenbostel T et al. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens 2012; 6 (1): 66–72.
10. Lindamood C, Ortiz S, Shaw A et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011; 51 (4): 575–85.
11. Lewin A, Punzi H, Luo X et al. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther 2013. http://pii: S0149-2918(12)00730-8. doi: 10.1016/j.clinthera.2012.12.015
12. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011; 33 (9): 1150–61.
13. Greathouse M. Nebivolol efficacy and safety in patients with stage I–II hypertension. Clin Cardiol 2010; 33 (4): e20–7.
14. Germino FW, Lin Y, Pejović V, Bowen L. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I–II hypertension. Ther Adv Cardiovasc Dis 2012; 6 (5): 185–99.
15. Cağlar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1359–68.
16. Vinereanu D, Gherghinescu C, Ciobanu AO et al. Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens 2011; 29 (4): 809–17.
17. Soanker R, Naidu MU, Raju SB et al. Effect of b1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol 2012; 44 (3): 407–11.
18. Mahmud A, Feely J. B-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21 (6): 663–7.
19. Kampus P, Serg M, Kals J et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57 (6): 1122–8.
20. Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. Eur Rev Med Pharmacol Sci 2010; 14 (9): 749–58.
21. Badar VA, Hiware SK, Shrivastava MP et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol 2011; 43 (4): 437–40.
22. Merchant N, Rahman ST, Ferdinand KC et al. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens 2011; 25 (3): 196–202.
23. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007; 27 (12): 841–9.
24. Martiniuc C, Branishte T. The use of b-blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev Med Chir Soc Med Nat Iasi 2012; 116 (1): 218–21.
25. Espinola-Klein C, Weisser G, Jagodzinski A et al. b-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011; 58 (2): 148–54.
26. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011; 29 (7): 1448–56.
2. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using b-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50: 563–72.
3. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25.
4. Magid DJ, Shetterly SM, Margolis KL et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors vs b-blockers as second-line therapy for hypertension circ. Cardiovasc Qual Outcomes 2010; 3: 453–8.
5. Oğuz A, Uzunlulu M, Yorulmaz E et al. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethy larginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg 2007; 7 (4): 383–7.
6. Zepeda RJ, Castillo R, Rodrigo R et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol 2012; 111 (5): 309–16.
7. Feng MG, Prieto MC, Navar LG. Nebivolol-induced vasodilation of renal afferent arterioles involves b3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol 2012; 303 (5): 775–82.
8. Lewin A, Lasseter KC, Dong F, Whalen JC. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. J Am Soc Hypertens 2012; 6 (3): 228–36.
9. Acelajado MC, Pisoni R, Dudenbostel T et al. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens 2012; 6 (1): 66–72.
10. Lindamood C, Ortiz S, Shaw A et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011; 51 (4): 575–85.
11. Lewin A, Punzi H, Luo X et al. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther 2013. http://pii: S0149-2918(12)00730-8. doi: 10.1016/j.clinthera.2012.12.015
12. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011; 33 (9): 1150–61.
13. Greathouse M. Nebivolol efficacy and safety in patients with stage I–II hypertension. Clin Cardiol 2010; 33 (4): e20–7.
14. Germino FW, Lin Y, Pejović V, Bowen L. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I–II hypertension. Ther Adv Cardiovasc Dis 2012; 6 (5): 185–99.
15. Cağlar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1359–68.
16. Vinereanu D, Gherghinescu C, Ciobanu AO et al. Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens 2011; 29 (4): 809–17.
17. Soanker R, Naidu MU, Raju SB et al. Effect of b1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol 2012; 44 (3): 407–11.
18. Mahmud A, Feely J. B-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21 (6): 663–7.
19. Kampus P, Serg M, Kals J et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57 (6): 1122–8.
20. Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. Eur Rev Med Pharmacol Sci 2010; 14 (9): 749–58.
21. Badar VA, Hiware SK, Shrivastava MP et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol 2011; 43 (4): 437–40.
22. Merchant N, Rahman ST, Ferdinand KC et al. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens 2011; 25 (3): 196–202.
23. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007; 27 (12): 841–9.
24. Martiniuc C, Branishte T. The use of b-blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev Med Chir Soc Med Nat Iasi 2012; 116 (1): 218–21.
25. Espinola-Klein C, Weisser G, Jagodzinski A et al. b-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011; 58 (2): 148–54.
26. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011; 29 (7): 1448–56.
Авторы
Л.О.Минушкина
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ
minushkina@mail.ru
minushkina@mail.ru
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ
minushkina@mail.ru
________________________________________________
minushkina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.